

Freedom of Information Team
De La Court House
Queen Alexandra Hospital
Southwick Hill Road
Portsmouth
Hampshire
PO6 3LY

Date: 11/05/2022 Ref: 21-22 624

## Freedom of Information request

Firstly, please accept our sincere apologies for the delay in providing you with a response.

Thank you for your request for information under the Freedom of Information Act 2000, which was received by the Trust on 08/03/2022. Please see responses to your requests below.

I am investigating the use of targeted therapies in blood-related cancers. Could you please tell me how many patients have you treated in the last 3 months for Multiple Myeloma?

There were 185 patients treated in the last 3 months for Multiple Myeloma.

## Further, how many have received the following treatments?

Treatment	Patients
Bortezomib [Velcade] and Dexamethasone	0
Bortezomib [Velcade], Thalidomide and Dexamethasone	8
[known as VTD]	U
Bortezomib [Velcade], Cyclophosphamide/Melphalan	
and Dexamethasone/Prednisolone [known as VCD or	9
VMP]	
Lenalidomide [Revlimid] monotherapy	21
Lenalidomide [Revlimid] and Dexamethasone	0
Lenalidomide [Revlimid], Bortezomib [Velcade] and	0
Dexamethasone	U
Lenalidomide [Revlimid], Melphalan and Prednisolone	0
Thalidomide, Cyclophosphamide/Melphalan, and	<4
Dexamethasone/Prednisolone [known as MPT or CTD]	
Bortezomib [Velcade] monotherapy	0
Carfilzomib [Kyprolis] and Dexamethasone	<4
Carfilzomib [Kyprolis], Lenalidomide [Revlimid], and	0
Dexamethasone [known as KRD]	
Daratumumab [Darzalex], Velcade [Bortezomib] and	37
Dexamethasone [known as DVD]	01

Daratumumab [Darzalex], Velcade [Botezomib], Thalidomide and Dexamethasone [known as Dara-VTd]	0
Daratumumab [Darzalex], Lenalidomide [Revlimid] and	0
Dexamethasone	
Daratumumab [Darzalex], Pomalidomide [Imnovid] and	0
Dexamethasone (DaraPd)	
Daratumumab [Darzalex] monotherapy	21
Isatuximab [Sarclisa], Pomalidomide [Imnovid] and	<4
Dexamethasone [known as IsaPd]	
Isatuximab [Sarclisa], Carfilzomib [Kyprolis] and	0
Dexamethasone [known as IsaKd]	
Ixazomib [Ninlaro], Lenalidomide [Revlimid] and	0
Dexamethasone [known as IRD]	
Pomalidomide [Imnovid] and Dexamethasone	10
Panobinostat [Farydak], Bortezomib [Velcade] and	<4
Dexamethasone	
Any other systemic anti-cancer treatment	160

We are unable to provide precise figures when these are four or less due to the risk that individuals will be identified, as we are required to protect their identity under the Data Protection Act.

In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle which, in our view, would be breached by disclosure.

Please accept this letter as completion of your request. Please note that copies of this request will be held on file for three years before being confidentially destroyed.

If you are dissatisfied with the outcome of your request, please contact our Head of Information Governance on <a href="mailto:Information.Governance@porthosp.nhs.uk">Information.Governance@porthosp.nhs.uk</a> or write to the above address and we will conduct an internal review. Upon review, if you are still dissatisfied, you may appeal our decision by contacting the Information Commissioner's Office; for more information, please visit the ICO's website.

Please be aware, if we do not receive an appeal within 30 days of you receiving this letter, we will assume that you are satisfied with our response. If you have any further queries, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team

